Medpace Holdings, Inc.
MEDPHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. Valued at $15.36B, MEDP is a large-cap name in its sector. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
Market Cap
$15.36B
Beta
1.15
P/E (TTM)
33.90
P/E (Fwd)
28.68
EPS (TTM)
$15.86
EPS (Fwd)
$18.75
ROE
77.3%
ROA
17.5%
Cash
$652.7M
Total Debt
$146.1M
Free CF
$490.7M
52W Change
72.4%
Annual Financials
Cash vs Debt
With $652.7M in cash and $146.1M in debt, MEDP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $490.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 77.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 17.5% further supports the picture of efficient asset utilization. Revenue has grown from $1.46B (2022) to $2.53B (2025), reflecting a 73% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Medpace Holdings, Inc. and its sector.